Get the Stockscreener App
5.31
7.93%
0.39
After Hours:
5.20
-0.11
-2.07%
Artelo Biosciences Inc stock is traded at $5.31, with a volume of 190.88K.
It is up +7.93% in the last 24 hours and down -45.37% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$4.92
Open:
$4.85
24h Volume:
190.88K
Relative Volume:
0.29
Market Cap:
$3.74M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-1.6804
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
+17.74%
1M Performance:
-45.37%
6M Performance:
-6.84%
1Y Performance:
-23.71%
1-Day Range:
$4.85
$5.75
1-Week Range:
$4.4068
$5.75
52-Week Range:
$4.20
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
5.31 | 6.38M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences launches public offering; shares down 10% - MSN
Artelo Biosciences Updates Bylaws on September 9, 2025 - TipRanks
Artelo Biosciences Announces Publication of Preclinical - GlobeNewswire
Superior Depression & Anxiety Results: Artelo's Novel CBD Cocrystal Shows Breakthrough Bioavailability - Stock Titan
Published on: 2025-09-09 14:57:14 - beatles.ru
Order Flow Trends Show Accumulation in Artelo Biosciences Inc.July 2025 Trends & Growth-Oriented Investment Plans - beatles.ru
Artelo Biosciences Inc. Rebound Backed by Sentiment ShiftMarket Growth Summary & Smart Swing Trading Techniques - beatles.ru
D. Boral Capital downgrades Artelo Biosciences stock rating to Hold from Buy By Investing.com - Investing.com South Africa
Artelo Biosciences Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Summary & Weekly Return Optimization Alerts - beatles.ru
Artelo Biosciences Announces Closing of $3.0 Million Public Offering - MarketScreener
D. Boral Capital downgrades Artelo Biosciences stock rating to Hold from Buy - Investing.com
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital - GuruFocus
Price action breakdown for Artelo Biosciences Inc.Rate Cut & Consistent Return Strategy Ideas - Newser
Sentiment analysis tools applied to Artelo Biosciences Inc.July 2025 EndofMonth & Pattern Based Trade Signal System - Newser
Published on: 2025-09-06 13:10:32 - Newser
How to use a screener to detect Artelo Biosciences Inc. breakouts2025 Market Sentiment & Daily Profit Focused Screening - Newser
Artelo Biosciences closes $3 million public offering of common stock By Investing.com - Investing.com Canada
Is Artelo Biosciences Inc. a turnaround story2025 Trading Recap & Fast Momentum Stock Entry Tips - خودرو بانک
Artelo Biosciences' $3.0M Raise and Strategic Implications for Clinical Advancement and Shareholder Value - AInvest
Artelo Biosciences Closes $3 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq
Artelo Biosciences closes $3 million public offering of common stock - Investing.com India
Artelo Biosciences Announces Closing of $3.0 Million Public Offe - GuruFocus
Artelo Biosciences Closes $3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences Completes $3 Million Public Offering - AInvest
Clinical-Stage Biotech Artelo Biosciences Secures $3M Through Public Offering at $4.40 Per Share - Stock Titan
Artelo Biosciences 15min Chart Triggers KDJ Golden Cross, Bullish Marubozu Candle - AInvest
Form 424B5 ARTELO BIOSCIENCES, INC. - StreetInsider
NuCana Achieves Nasdaq Compliance, Anticipates Funding Until 2029 - AInvest
Leading vs lagging indicators on Artelo Biosciences Inc. performanceJuly 2025 Reactions & Safe Capital Growth Tips - Newser
Artelo Biosciences Inc. stock trend outlook and recovery path2025 Key Lessons & Consistent Growth Equity Picks - Newser
Ranking Artelo Biosciences Inc. among high performing stocks via toolsProduct Launch & Real-Time Buy Signal Notifications - Newser
Artelo Biosciences prices $3 million public offering of common stock By Investing.com - Investing.com Canada
Artelo Biosciences Raises $3mln Through Common Stock and Warrant Offering - AInvest
Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq
Artelo Biosciences announces pricing of $3 million public offering - MSN
How to read the order book for Artelo Biosciences Inc.Portfolio Return Report & Low Drawdown Trading Strategies - Newser
Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results - Benzinga
Artelo Biosciences Plummets 51%: A Tale of Triumph and Turmoil in Biotech's High-Stakes Arena - AInvest
Artelo Biosciences Plummets 51%: Can Positive Trial Results Salvage Investor Confidence? - AInvest
Artelo Biosciences announces pricing of $3.0 million public offering - MarketScreener
Can Artelo Biosciences Inc. sustain its profitabilityCPI Data & Community Driven Trade Alerts - خودرو بانک
Artelo Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Artelo Biosciences prices $3 million public offering of common stock - Investing.com
Artelo Biosciences Prices $3 Million Offering; Shares Fall 50% Pre-Bell - MarketScreener
Artelo Biosciences Plunges 28.08% on Public Offering Announcement - AInvest
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering - The Manila Times
Artelo Biosciences Announces $3M Public Offering of Common Stock and Warrants. - AInvest
$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research - Stock Titan
Artelo Biosciences Launches Public Offering with Undetermined Size and Terms - AInvest
Artelo Biosciences Plunges 14.38% on Public Offering Announcement - AInvest
Custom strategy builders for tracking Artelo Biosciences Inc.July 2025 Opening Moves & Community Consensus Stock Picks - Newser
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):